Introduction
============

Urinary bladder cancer is the ninth most common malignancy worldwide, and the common histological type is urothelial carcinoma (UC) [@B1]-[@B3]. Although cisplatin-based systemic chemotherapy is used to treat advanced diseases, urinary bladder urothelial carcinoma (UBUC) still ranks 13th as a cause of cancer death [@B2]. More than 90% of UCs arise in the urinary bladder, and only 5% to 10% of all UCs develop in the upper urinary tract [@B1]-[@B3]. Although growing evidence has suggested that UBUC and upper urinary tract UC (UTUC) may share several biologically unique features, there are certain significant similarities between both types of UCs [@B4]-[@B9]. Additionally, it was reported that there was a 30-50% risk of bladder recurrence within 5 years for patients with UTUC receiving radical nephroureterectomy and a 2-6% risk of developing subsequent UTUC after initial diagnosis with UBUC [@B10]-[@B11]. Furthermore, the behavior of both diseases is identical after adjusting for tumor stage and histological grade [@B6]-[@B7]. We therefore hypothesized that both UTUC and UTUB may share similar tumorigenesis pathways.

Regardless of the inciting mechanism and/or long-term behavior, further elucidation of the molecular basis of UBUC and UTUC will have important implications in understanding the differences or similarities in the genetic profiles as well as identifying prognostic biomarkers to develop novel targeted therapy. To address this, we performed data mining from a published transcriptome of UBUC (GSE31684), identifying RING finger protein 128 (*RNF128*) as the most significant gene for cancer invasiveness and metastasis among those associated with negative regulation of the cytokine biosynthetic process (GO:0042036).

RNF128 (also known as Grail, a gene related to anergy in lymphocytes) is an E3 ubiquitin ligase functioning as a regulator of anergy and cytokine production [@B12]-[@B14]. It was shown to play an important role in controlling Th2 development through a negative feedback loop [@B13]-[@B14]. A recent report found that RNF128 was a p53-interacting glycoprotein and may be crucial in p53-induced apoptosis under variable stress conditions [@B12]. The transcription factor p53, a well-known tumor suppressor encoded by the *TP53* gene, regulates genes critical for cell cycle arrest, senescence and apoptosis to maintain genome stability [@B15]-[@B17]. *TP53,* the most frequently mutated gene, has been identified in approximately 50% of all human cancers [@B15]-[@B19]. Moreover, p53 is one of the most commonly studied markers in UC [@B20]-[@B22].

While the crucial role that p53 plays in cancers is apparent, the involvement of RNF128 in tumorigenesis remains unknown, and little if any research has investigated its function [@B12]. To our knowledge, this is the first study to elucidate the relationship between RNF128 expression and clinical presentation in patients with UBUC and UTUC. We also aimed to comprehensively analyze its expression and associated clinicopathological factors as well as disease survival in our well-characterized cohort of UC patients.

Materials and Methods
=====================

Analysis of a public transcriptomic dataset of UC
-------------------------------------------------

To identify relevant genes that are critical in the pathogenesis of UC, we performed data mining on GEO (National Center Biotechnology Information) and identified a dataset (GSE31684) which profiled radical cystectomy specimens from 93 patients with UBUC using an Affymetrix U133 Plus 2.0 Array. To analyze the gene expression levels, we imported the raw CEL files into Nexus Expression 3 (BioDiscovery, EI Segundo, CA, USA). All probe sets were tested without preselection or filtering. Supervised comparative analysis and functional profiling were carried out to identify statistically significant genes that were associated with negative regulation of the cytokine biosynthetic process (GO:0042036). The statistical significance of differentially expressed transcripts was determined, and transcripts were chosen to validate on the basis of primary tumor (pT) status and the development of metastatic events. We performed a detailed comparison between the differential expression in low-stage (pTa-pT1) UCs and high-stage (pT2-pT4) UCs as well as UC with and without distal metastasis. All cases were dichotomized into two groups, high- and low-expression, to assess the prognostic impact of selected gene using survival analyses.

Patient characteristics and tumor specimens
-------------------------------------------

A total of 635 UC patients (340 UTUCs and 295 UBUCs) were enrolled as the subjects of the study, and the data were retrieved from the archives of Chi-Mei Medical Center between 1996 and 2004. Other histological variants and synchronous UTUC and UBUC were excluded. The study protocol and the paraffin-embedded tissue blocks used for immunohistochemistry were approved by the institutional review board (IRB10302015). All patients with UTUC underwent nephroureterectomy with bladder cuff excision and regional lymph node (LN) dissection, while those with superficial UBUC (pTa-pT1) received transurethral resection of the bladder tumor (TUR-BT), with or without subsequent intravesical BCG injection. Radical cystectomy was performed as a salvage treatment for UBUC recurrence. For muscle-invasive UBUC, radical cystectomy with bilateral pelvic LN dissection was performed. Patients who had advanced UBUC disease, i.e., pT3 or pT4 and/or LN metastasis, were treated with systemic adjuvant chemotherapy after the surgical removal of all gross lesions. In comparison, only 29 of the 106 UTUC patients with pT3 or pT4 stage and/or nodal involvement received adjuvant chemotherapy. The criteria for the clinicopathological evaluation were essentially identical to our previous studies [@B23]-[@B28].

Real-time RT-PCR
----------------

For quantification of *RNF128* transcript levels in urothelial cells, total RNAs from urothelial cancer cells were extracted for reverse-transcription PCR. Pre-designed TaqMan probes targeting *RNF128* (Hs00226053_m1) were used to measure the mRNA levels with an ABI StepOnePlus™ System as described in our previous studies [@B26], [@B28]. After normalization to the internal control of *POLR2A* (Hs01108291_m1), the expression of RNF128 relative to that of normal urothelium was determined by the comparative Ct method.

Immunohistochemical staining and scoring of RNF128
--------------------------------------------------

For immunohistochemistry, paraffin-embedded tissue blocks were sectioned at a thickness of 4 μm,

deparaffinized, and rehydrated. Subsequently, the sections were incubated with a primary antibody targeting RNF128 (1:200, Rabbit monoclonal \[EPR7426(2)\], Abcam) for an hour after quenching endogenous peroxidase activity with saline for 15 minutes. RNF128 immunostaining was examined by two independent pathologists (P.I.L and C.F.L), who were unaware of the patients\' clinicopathological characteristics. Scoring of RNF128 immunoreactivity was determined based on a combination of the percentage and intensity of positive cytoplasmic staining to obtain the H-score, which was calculated using the following equation: H-score=ΣPi(i+1). In this formula, i represents the intensity of the stained tumor cells (0-3+), and Pi is the percentage of stained tumor cells for each intensity varying from 0% to 100%, with an obtained score ranging from 100-400. The score 100 indicated that 100% of tumor cells were negative, and 400 indicated that 100% of tumor cells showed an intense, strong staining (3+) [@B23]-[@B28]. Concordance for interpretation of RNF128 between the two pathologists was above 90%. For those with discrepancies of the histological slides, cases were then independently reanalyzed, resulting in consensus scores.

Cell lines and culture conditions
---------------------------------

Four UC cell lines, RT4, RT9 (formally known as RTCC-1/KMC), J82, and TSGH8301, were grown based on the suggested media and conditions as described in our previous research studies [@B29], [@B30].

Western blot assays
-------------------

Equal amounts of total cellular protein (25 μg) extracts were separated on 4%-12% gradient sodium dodecyl sulfate polyacrylamide gels, transferred to polyvinylidene difluoride membranes and then probed with antibodies against RNF128 (1:1000, Rabbit monoclonal \[EPR7426(2)\], Abcam) with protocols identical to our previous publications [@B28].

Statistical analysis
--------------------

The statistical software package (V.14.0, SPSS Inc., Chicago, Illinois, USA) was used for all data entry and analysis. The median H-score of RNF128 was used as the cut-off to dichotomize the study cohort, separating cases into high- and low-expression groups. The chi-square test was used to compare the RNF128 expression status and the clinicopathological variables tested. The end points analyzed were disease-specific survival (DSS) and metastasis-free survival (MeFS), calculated from the starting date of resection of the tumors to the date of event developed. Patients lost to follow-up were censored on the latest follow-up date. Kaplan-Meier plots and the log-rank test were used to detect significant differences in univariate survival analyses. Those parameters with univariate p\<0.1 were included in multivariate analyses using Cox proportional hazards regression. For all analyses, two-sided tests were performed, with p\<0.05 set as significant.

Results
=======

RNF128 identified as a significant differentially downregulated transcript involved in dysregulation of cell growth in UBUC
---------------------------------------------------------------------------------------------------------------------------

From the transcriptomic profile, 7 probes covering 3 transcripts associated with negative regulation of the cytokine biosynthetic process (GO:0042036) were analyzed. *RNF128* was the only significant gene that met the study selection criteria (Figure [1](#F1){ref-type="fig"} and Table [1](#T1){ref-type="table"}). Downregulation of *RNF128* showed a significant association with primary tumor status increases (log~2~ ratio, -2.385; p\<0.0001) and distal metastasis (log~2~ ratio, -1.1327; p=0.0093). In light of these findings, we were prompted to investigate endogenous RNF128 levels and their clinical significance in our well-characterized UC cohort.

Clinicopathological findings in UTUC and UBUC
---------------------------------------------

Table [2](#T2){ref-type="table"} presents the clinicopathological findings of the UTUC and UBUC cases. While the UTUC patients showed relatively even distribution across both sexes, male sex accounted for the majority of the UBUC patients (n=216, 73.2%). Most cases in the UTUC and UBUC groups were older than 65 years (n=202, 59.4% for UTUC; n=174, 60.0% for UBUC). In the UTUC group, a total of 62 patients (18.2%) had multifocal diseases, 49 (14.4%) of which presented with synchronous tumor involvement of the renal pelvis and ureter. Advanced pT stages (pT2-pT4) were identified in 159 (46.8%) and 123 (41.7%) of the UTUC and UBUC cases, respectively. Nodal involvement was identified in 28 (8.2%) and 29 (23.6%) of the UTUC and UBUC patients, respectively. More than 80% of the UC patients in both groups had a high histological grade (n=284, 83.5% for UTUC; n=239, 81.0% for UBUC). Other relevant histological findings of significance including vascular and perineural invasion as well as a high mitotic rate. A more detailed description of the results is provided in Table [2](#T2){ref-type="table"}.

Correlations between immunoreactivity of RNF128 and parameters in UTUC and UBUC
-------------------------------------------------------------------------------

RNF128 showed variable cytoplasmic expression in UC of both anatomic sites. As shown in Table [2](#T2){ref-type="table"}, downregulated RNF128 expression in urothelial carcinoma of both sites was significantly correlated with stepwise increases in pT stage (**Figure [2](#F2){ref-type="fig"}**, p\<0.001 for both UTUC and UBUC), nodal metastasis (UTUC, p\<0.001; UBUC, p=0.001), high histological grade (UTUC, p\<0.001; UBUC, p=0.035), vascular invasion (UTUC, p\<0.001; UBUC, p=0.008), and high mitotic rate (UTUC, p=0.003; UBUC, p=0.023). Downregulation of RNF128 expression was significantly associated with perineural invasion in UTUC patients (p\<0.001).

Survival analysis of UTUC and UBUC
----------------------------------

The results of the univariate and multivariate analyses of association between clinical outcomes and several clinicopathological variables in both UTUC and UBUC patients are shown in Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}, respectively. Univariate analysis indicated that poor DSS was significantly associated with tumor location (p=00079), multifocality (p=0.0026), higher pT status (p\<0.0001), nodal metastasis (p\<0.0001), high histological grade (p= 0.0215), vascular invasion (p\<0.0001) and perineural invasion (p\<0.0001) in UTUCs. Similar results were also found with MeFS, except for tumor location. In the UTUC group, only nodal metastasis (both p\<0.001) and perineural invasion (both p=0.002) remained significantly correlated with worse DSS and MeFS in multivariate comparisons.

In the UBUC group, univariate analysis showed that poor DSS was significantly associated with higher pT status (p\<0.0001), nodal metastasis (p=0.0002), high histological grade (p= 0.0013), vascular invasion (p=0.0024), perineural invasion (p\<0.0001) and high mitotic rate (p\<0.0001). The relevant findings for MeFS were similar. Multivariate analysis revealed that advanced pT stage was significantly associated with poor DDS and MeFS (p\<0.0001 and p= 0.009, respectively). High mitotic rate was also significantly correlated with poor DSS or MeFS (p=0.016 and p=0.028, respectively) in the multivariate analysis.

Prognostic value of RNF128 expression in UCs
--------------------------------------------

Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"} show that low RNF128 cytoplasmic expression in univariate analysis was significantly related to poor DSS and MeFS in patients with either UTUC or UBUC (**Figure [3](#F3){ref-type="fig"}**). In addition, downregulated RNF128 expression still remained an independent prognosticator of poor DSS (UTUC, p=0.006; UBUC, p=0.003) and MeFS (UTUC, p=0.009; UBUC, p=0.036) in the multivariate comparisons.

RNF128 was downregulated in invasive urothelial cancer cells
------------------------------------------------------------

According to the Western blot and Real-time RT-PCR analysis, *RNF128* transcript and protein were detected with high expression in RT4, which is a cell line derived from a non-invasive and low-grade urothelial cancer. While its expression was barely detected in invasive urothelial cancer cells including RT9, J82, and TSGH8301 (**Figure [4](#F4){ref-type="fig"}**).

Discussion
==========

Through data mining of the GEO data set GSE31684, we found that RNF128 expression was downregulated in UBUC compared to normal urothelium. Using immunohistochemistry, we showed that RNF128 expression in both UTUC and UBUC was significantly lower in advanced disease and was correlated with high tumor stage, high histological grade, high proliferation, and the presence of vascular and perineural invasion. Furthermore, downregulation of RNF128 was independently correlated with unfavorable outcomes in UC. To our knowledge, this is the first study to investigate the expression level and biological function of RNF128 in both UTUC and UBUC. Our findings indicated that downregulated RNF128 expression is a characteristic of poorly differentiated aggressive tumors. These results are consistent with those of Chen et al. [@B12]. Their unpublished data showed that RNF128 expression appeared to be downregulated in oral cancers through epigenetic modifications [@B12].

While the most reliable known prognostic factors for UBUC are tumor stage and histological grade, there have been multiple identified predictive markers for UTUC, including tumor multiplicity, anatomic ureteric location, tumor stage and high histological grade [@B4]-[@B11], [@B31]-[@B32]. However, these pathological features are not sufficient to accurately predict the evolution and progression of tumor invasion, especially for UTUC and UBUC. The utility and importance of biomarkers has been recognized and may help refine the understanding of the biological behavior of UTUC and UBUC, thereby improving the risk stratification and clinical management. Our study, for the first time, showed that low RNF128 expression was a promising molecular biomarker for the outcomes of both UTUC and UBUC. In addition, the results also indicated that UCs from both anatomical sites may share a common molecular pathway for tumorigenesis.

Alterations of the *TP53* tumor suppressor gene play a central role in the carcinogenesis of many tumors, including UC [@B20]-[@B22]. The *TP53* gene, located on the short arm of chromosome 17 (17p13.1), encodes a 393 amino acid protein (p53) that regulates the cell cycle, DNA repair, and apoptosis [@B21]. *TP53* mutations result in a series of downstream effects, including decreased expression of p21 [@B12], [@B20]-[@B22]. *TP53*mutations in UC are also related to higher tumor grade, advanced stage, and worse disease outcomes [@B21]-[@B22]. Downregulated expression of RNF128 was found to be involved in p53-induced apoptosis, playing an essential role in determining the cell fate, by Chen et al. [@B12]. The present study showed that RNF128 expression in UC was downregulated in samples with high tumor stages and histological grades and was associated with poorer patient outcomes. These results suggest that downregulation of RNF128 provides a growth advantage during UC tumorigenesis via p53 inactivation [@B33]-[@B35].

RNF128 functions as an E3 ubiquitin-protein ligase and has been characterized as a negative regulator of T-cell receptor responsiveness and cytokine production [@B12]-[@B13]. MDM2, a RING-type E3 of the ubiquitin proteasome system (UPS), is the main regulator of the p53 tumor suppressor protein, and targeting MDM2 by small molecules that prevent binding/ubiquitination of p53 has been of great research interest in recent years [@B36]. Four compounds that block the MDM2-p53 interactions are currently being assessed in phase I clinical trials [@B33]-[@B34]. RNF128, which has a similar role to MDM2 in the p53-MDM2 negative feedback loop, may be a promising therapeutic target through mediation of p53 ubiquitination [@B12], [@B36]-[@B37]. Therefore, it would be of interest to test this strategy of targeted treatment in UC in the future.

Finally, there is an interesting issue with regard to the crosstalk between RNF128 and MDM2 for the regulation of p53 functions [@B12]. High activity of MDM2 has been observed in different cancers, leading to the reduction or loss of the p53 protein through ubiquitination, nuclear export, and transcriptional regulation [@B38]-[@B39]. *TP53* mutation and *MDM2* amplification were mutually exclusive events in the tumorigenesis of UC, both were correlated with greater recurrence and lower survival rate [@B40]-[@B41]. Although the p53-binding glycoprotein RNF128 was shown to function in a similar manner to that of MDM2 in the negative feedback loop, downregulation of RNF128 expression was observed in our present study as well as unpublished data by Chen et al. [@B12], in contrast to the usual overexpression of MDM2 in cancers. RNF128 appeared to be a key player in cell fate in p53-dependent apoptosis and cell cycle arrest [@B12]. Based on our present study results, we hypothesized that downregulated RNF128 expression exert a cooperative effect impacting tumor progression and survival in conjunction with p53-mediated pathway but not with MDM2 amplification. More research will be necessary to elucidate these effects.

Deregulated cell-cycle control and alterations in the ubiquitylation of cell-cycle regulators such as E3 ubiquitin ligases might lead to uncontrolled cell proliferation as well as genomic instability and have been shown to be implicated in many human malignancies [@B42]-[@B43]. Sahoo et al [@B13] found that the novel E3 ubiquitin ligase, RNF128, might play an important role in controlling Th2 development by targeting signal transducer and activator of transcription 6 (STAT6) [@B13]. GATA binding protein 3 (GATA3), a transcriptional factor downstream of STAT6, was also suggested to regulate RNF128 expression among those participating in Th2 cells depending interleukin (IL)-4 components [@B13], [@B44]. Previous studies have identified STAT6 as a crucial cell differentiation modulator in human breast cancer cells through IL-4-mediated growth inhibition and induction of apoptosis [@B45]-[@B46]. Followed by the utility in the differentiation of mammary epithelia, GATA3 has been identified as novel marker for the diagnosis of urothelial carcinoma [@B47]. Moreover, GATA3 was found to be downregulated in higher grade breast cancer and invasive bladder cancer [@B47]-[@B48]. In the present study, we showed that downregulation of RNF128 expression was correlated with higher tumor stage in invasive urothelial carcinoma. This tendency was in parallel with GATA3 expression seen in previous studies. We therefore supposed that downregulated GATA3 expression resulted in lower RNF128 expression in higher grade invasive urothelial carcinoma, which may be involved by STAT6 or not. Further investigation would be addressed on a need bases. Additionally, endogenous RNF128 expression was shown to participate in the cell cycle and promotes the proliferation of primary naive CD4 T-cells as aforementioned findings [@B13]-[@B14]. Thus, it would be of interest to study the role of RNF128 during T-cell unresponsiveness and whether it may serve as a possible target in immunotherapy for cancer treatment [@B13]-[@B14].

Moreover, downregulation of RNF128 expression is an independent predictor for UTUC and UBUC. Our findings suggest that RNF128 is not only a diagnostic biomarker but also a prognostic biomarker in UC. Further evaluation to elucidate the biological significance of dysregulated RNF128 expression in UC is needed to explore the potential of RNF128-targeted therapy in UC.
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![Data mining on a public transcriptomic dataset of urothelial carcinoma. By reappraising the published transcriptomic dataset of urinary bladder urothelial carcinoma (GSE31684), RNF128 is identified as the most significantly downregulated gene associated with cancer invasiveness and metastasis in clustering analysis focusing on cytokine biosynthetic process (GO:0042036). Specimens from high pT (blue lines) and low pT (yellow lines) are indicated on top of the heatmap, and upregulation and downregulation of genes are illustrated as a spectrum of brightness of red and green, respectively. Those with unaltered mRNA expression are coded as black.](jcav07p2187g001){#F1}

![Immunohistochemical staining for RNF128 in representative case. (A) Intact expression of RNF128 in the non-neoplastic urothelium (upper and upper inset) is seen, compared with the weaker staining in the non-invasive urothelial carcinoma component (middle and lower, lower inset). (B) High-grade invasive urothelial carcinoma exhibits very low expression of RNF128 (inset).](jcav07p2187g002){#F2}

![Survival analysis by Kaplan-Meier plots. Downregulation of RNF128 immunointensity confers poor disease-specific survival (DSS) and metastasis-free survival (MFS) in both upper tract urothelial carcinoma (UTUC, A and B) and urinary bladder urothelial carcinoma patients (UBUC, C and D).](jcav07p2187g003){#F3}

![Endogenous RNF128 expression levels determined by quantitative RT-PCR (A) and western blotting assays (B). RNF128 expression is barely detected in invasive urothelial cancer cells including RT9, J82, and TSGH8301 while its expression is high in RT4, a cell line derived from a non-invasive and low-grade urothelial cancer.](jcav07p2187g004){#F4}

###### 

Summary of differentially expressed genes associated with negative regulation of cytokine biosynthetic process (GO:0042036) and showed positive associations to cancer invasiveness and metastasis in the transcriptome of urinary bladder urothelial carcinoma (GSE31684).

  Probe       Comparing T2-4 to Ta-T1   Comparing Meta. to Non-Meta.^\#^   Gene Symbol   Gene Title   Molecular Function                             
  ----------- ------------------------- ---------------------------------- ------------- ------------ -------------------- ------------------------- ----------------------------------------------------------------------------------------------------------
  219263_at   -2.385                    \<0.0001                           -1.1327       0.0093       ***RNF128***         RING finger protein 128   ligase activity, metal ion binding, protein binding, ubiquitin-protein ligase activity, zinc ion binding

\#, Meta., distal metastasis developed during follow-up; Non-Meta.: no metastatic event developed.

###### 

Correlations between RNF128 Expression and other important clinicopathological parameters in urothelial carcinomas.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter\                                Category\       Upper Urinary Tract Urothelial Carcinoma   Urinary Bladder Urothelial Carcinoma                                           
  ----------------------------------------- --------------- ------------------------------------------ -------------------------------------- ----- --------------- ----- ----- ----- ---------------
  Gender                                    Male            158                                        78                                     80    0.277           216   104   112   0.339

  Female                                    182             92                                         90                                           79              43    36          

  Age (years)                               \< 65           138                                        68                                     70    0.825           121   64    57    0.380

  ≥ 65                                      202             102                                        100                                          174             83    91          

  Tumor location                            Renal pelvis    141                                        67                                     74    0.727           \-    \-    \-    \-

  Ureter                                    150             77                                         73                                           \-              \-    \-    \-    

  Renal pelvis & ureter                     49              26                                         23                                           \-              \-    \-    \-    

  Multifocality                             Single          278                                        140                                    138   0.779           \-    \-    \-    \-

  Multifocal                                62              30                                         32                                           \-              \-    \-    \-    

  Primary tumor (T)                         Ta              89                                         69                                     20    **\<0.001\***   84    57    27    **\<0.001\***

  T1                                        92              55                                         37                                           88              49    39          

  T2-T4                                     159             46                                         113                                          123             41    82          

  Nodal metastasis                          Negative (N0)   312                                        167                                    145   **\<0.001\***   266   141   125   **0.001\***

  Positive (N1-N3)                          28              3                                          25                                           29              6     23          

  Histological grade                        Low grade       56                                         45                                     11    **\<0.001\***   56    35    21    **0.035\***

  High grade                                284             125                                        159                                          239             112   127         

  Vascular invasion                         Absent          234                                        138                                    96    **\<0.001\***   246   131   115   **0.008\***

  Present                                   106             32                                         74                                           49              16    33          

  Perineural invasion                       Absent          321                                        168                                    153   **\<0.001\***   275   141   134   0.066

  Present                                   19              2                                          17                                           20              6     14          

  Mitotic rate (per 10 high power fields)   \< 10           173                                        100                                    73    **0.003\***     139   79    60    **0.023\***

  \>= 10                                    167             70                                         97                                           156             68    88          
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Statisttically significant.

###### 

Univariate log-rank and multivariate analyses for Disease-specific and Metastasis-free Survivals in upper urinary tract urothelial carcinoma.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter\              Category       Case No.   Disease-specific Survival   Metastasis-free Survival                                                                         
  ----------------------- -------------- ---------- --------------------------- -------------------------- -------------- ---- ------- ---- ---------------- -------------- ---- -------------
  **Gender**              Male           158        28                          0.8286                     \-             \-   \-      32   0.7904           \-             \-   \-

  Female                  182            33                                     \-                         \-             \-   38           \-               \-             \-   

  **Age (years)**         \< 65          138        26                          0.9943                     \-             \-   \-      30   0.8470           \-             \-   \-

  ≥ 65                    202            35                                     \-                         \-             \-   40           \-               \-             \-   

  **Tumor side**          Right          177        34                          0.7366                     \-             \-   \-      38   0.3074           \-             \-   \-

  Left                    154            26                                     \-                         \-             \-   32           \-               \-             \-   

  Bilateral               9              1                                      \-                         \-             \-   0            \-               \-             \-   

  **Tumor location**      Renal pelvis   141        24                          **0.0079\***               1              \-   0.560   31   0.0659           \-             \-   \-

  Ureter                  150            22                                     0.859                      0.460-1.602         25           \-               \-             \-   

  Renal pelvis & ureter   49             15                                     1.845                      0.491-6.935         14           \-               \-             \-   

  **Multifocality**       Single         273        48                          **0.0026\***               1              \-   0.482   52   **0.0127\***     1              \-   **0.001\***

  Multifocal              62             18                                     1.578                      1.400-6.540         18           2.790            1.563-4.980         

  **Primary tumor (T)**   Ta             89         2                           **\<0.0001\***             1              \-   0.130   4    **\<0.0001\***   1              \-   0.135

  T1                      92             9                                      3.123                      0.654-14.903        15           3.216            0.678-15.265        

  T2-T4                   159            50                                     4.633                      1.005-21.347        51           4.606            1.005-21.116        
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Statistically significant.

###### 

Univariate log-rank and multivariate analyses for Disease-specific and Metastasis-free Survivals in urinary bladder urothelial carcinoma.

  Parameter                                 Category        Case No.   Disease-specific Survival   Metastasis-free Survival                                                                        
  ----------------------------------------- --------------- ---------- --------------------------- -------------------------- --------------- ---- --------- ---- ------------ -------------- ---- ---------
  Gender                                    Male            216        41                          0.4446                     \-              \-   \-        60   0.2720       \-             \-   \-
  Female                                    79              11                                     \-                         \-              \-   16             \-           \-             \-   
  Age (years)                               \< 65           121        17                          0.1136                     \-              \-   \-        31   0.6875       \-             \-   \-
  ≥ 65                                      174             35                                     \-                         \-              \-   45             \-           \-             \-   
  Primary tumor (T)                         Ta              84         1                           \<0.0001\*                 1               \-   0.001\*   4    \<0.0001\*   1              \-   0.009\*
  T1                                        88              9                                      5.706                      0.655-49.677         23             4.754        1.430-15.800        
  T2-T4                                     123             42                                     19.576                     2.351-163.031        49             6.533        1.951-21.881        
  Nodal metastasis                          Negative (N0)   266        41                          0.0002\*                   1               \-   0.753     61   \<0.0001\*   1              \-   0.075
  Positive (N1-N3)                          29              11                                     1.121                      0.524-2.169          15             1.767        0.943-3.311         
  Histological grade                        Low grade       56         2                           0.0013\*                   1               \-   0.731     5    0.0007\*     1              \-   0.988
  High grade                                239             50                                     1.312                      0.279-6.170          71             0.922        0.342-2.876         
  Vascular invasion                         Absent          246        37                          0.0024\*                   1               \-   0.254     54   0.0001\*     1              \-   0.790
  Present                                   49              15                                     0.666                      0.332-1.339          22             1.087        0.588-2.011         
  Perineural invasion                       Absent          275        44                          0.0001\*                   1               \-   0.037\*   66   0.0007\*     1              \-   0.143
  Present                                   20              8                                      2.444                      1.054-5.667          10             1.740        0.829-3.654         
  Mitotic rate (per 10 high power fields)   \< 10           139        12                          \<0.0001\*                 1               \-   0.016\*   23   \<0.0001\*   1              \-   0.028\*
  \>= 10                                    156             40                                     2.292                      1.169-4.491          53             1.785        1.065-2.992         
  RNF128 expression                         High            147        12                          \<0.0001\*                 1               \-   0.003\*   26   0.0002\*     1              \-   0.036\*
  Low                                       148             20                                     2.765                      1.406-5.437          50             1.712        1.035-2.830         

\*Statistically significant.
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